Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:35 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.
NCT04898504 · Oslo University Hospital · PHASE2 · terminated · last registry update 2026-10-22 · Colorectal cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Following temporary halt of inclusion in September 2024, several measures were taken, as previuosly reported. As numbers included by September 2024 were sufficient to conclude for primary endpont, we have decided not to restart the trial.” | – | Registry record, Oslo University Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TYMS in colorectal cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-04Phase 3 first posted: Innovent Biologics (Suzhou) Co. Ltd., Oxaliplatin + Placebo (NCT07917468)
- 2026-11-04Results posted on the registry: Jazz Pharmaceuticals, ZW25 (Zanidatamab) + Capecitabine (NCT03929666)
- 2026-11-03Also stopped (terminated): Peking University Cancer Hospital & Institute, KN046 + regorafenib (NCT05985109)
- 2026-10-30Results posted on the registry: Memorial Sloan Kettering Cancer Center, Bevacizumab HAI plus systemic chemotherapy + HAI plus systemic chemotherapy (NCT00200200)
- 2026-10-21Phase 3 first posted: West China Hospital, Fruquintinib Combined With Capecitabine (NCT07885384)
- 2026-10-02Also stopped (terminated): Ralf Hofheinz, mFOLFOX (neoadjuvant) + XELOX (neoadjuvant) (NCT04495088)
- 2026-10-02Also stopped (suspended): University of Alabama at Birmingham, ProAgio + FOLFIRI (NCT06867822)
- 2026-09-11Phase 3 first posted: Fudan University, Second-Line Chemotherapy + Cadonilimab (AK104) (NCT07815834)
- 2026-08-20Phase 3 first posted: Genmab, Petosemtamab + Cetuximab (NCT07775287)
- 2026-07-14Phase 3 first posted: Genmab, Petosemtamab + Cetuximab (NCT07702032)
- 2026-05-19Phase 3 first posted: Taizhou Mabtech Pharmaceutical Co.,Ltd, Enlituo® + Erbitux® (NCT07595276)
- 2026-04-14Results posted on the registry: National Cancer Institute (NCI), Atezolizumab + Fluorouracil (NCT02912559)
- 2026-03-03Results posted on the registry: Alliance for Clinical Trials in Oncology, Bevacizumab + Oxaliplatin (NCT04094688)
- 2025-12-09Phase 3 first posted: City of Hope Medical Center, Bevacizumab + Fluorouracil (NCT07271355)
- 2025-11-14Phase 3 first posted: Summit Therapeutics, Drug: Ivonescimab Injection + Drug: Bevacizumab Injection (NCT07228832)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision